» Articles » PMID: 26171588

TIGIT Expression Levels on Human NK Cells Correlate with Functional Heterogeneity Among Healthy Individuals

Overview
Journal Eur J Immunol
Date 2015 Jul 15
PMID 26171588
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Human NK cells display extensive phenotypic and functional heterogeneity among healthy individuals, but the mechanism responsible for this variation is still largely unknown. Here, we show that a novel immune receptor, T-cell immunoglobulin and ITIM domain (TIGIT), is expressed preferentially on human NK cells but shows wide variation in its expression levels among healthy individuals. We found that the TIGIT expression level is related to the phenotypic and functional heterogeneity of NK cells, and that NK cells from healthy individuals can be divided into three categories according to TIGIT expression. NK cells with low levels of TIGIT expression show higher cytokine secretion capability, degranulation activity, and cytotoxic potential than NK cells with high levels of TIGIT expression. Blockade of the TIGIT pathway significantly increased NK-cell function, particularly in NK cells with high levels of TIGIT expression. We further observed that the TIGIT expression level was inversely correlated with the IFN-γ secretion capability of NK cells in patients with cancers and autoimmune diseases. Importantly, we propose a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer.

Citing Articles

Agent-based modeling of cellular dynamics in adoptive cell therapy.

Wang Y, Casarin S, Daher M, Mohanty V, Dede M, Shanley M bioRxiv. 2025; .

PMID: 40027823 PMC: 11870559. DOI: 10.1101/2025.02.17.638701.


Kir6.1, a component of an ATP-sensitive potassium channel, regulates natural killer cell development.

Samper N, Hardardottir L, Depierreux D, Song S, Nakazawa A, Gando I Front Immunol. 2024; 15:1490250.

PMID: 39687626 PMC: 11646858. DOI: 10.3389/fimmu.2024.1490250.


Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.

McErlean E, McCarthy H J Nanobiotechnology. 2024; 22(1):552.

PMID: 39256765 PMC: 11384716. DOI: 10.1186/s12951-024-02746-4.


IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.

Badhrinarayanan S, Cotter C, Zhu H, Lin Y, Kudo M, Li D Future Oncol. 2024; 20(28):2049-2057.

PMID: 38861301 PMC: 11497967. DOI: 10.1080/14796694.2024.2355863.


NK-cell receptor modulation in viral infections.

Lenart M, Rutkowska-Zapala M, Siedlar M Clin Exp Immunol. 2024; 217(2):151-158.

PMID: 38767592 PMC: 11239562. DOI: 10.1093/cei/uxae045.